ArticleBreast cancer research and treatment2021

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.

Emanuel Raschi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.